fbpx

Day: October 19, 2021

Three years on, we need to relax cannabis regulation

Moving away from the ‘one size fits all’ approach would help make Canada’s legal cannabis market more consumer-friendly Author of the article:

Three years ago Sunday (October 17, 2018), Canada legalized adult-use recreational cannabis. The Trudeau government deserves credit for making this happen, as most Canadians had for some time believed that the consequences of prohibition outweighed whatever negatives would arise from legalization. That said, the Cannabis Act is now three years old, and it needs to be amended to make the legal cannabis market more consumer- and patient-friendly.

A good first step would be to remove “CBD” products from the Cannabis Act altogether. CBD stands for “cannabidiol,” a chemical found mainly in hemp, which itself is low in THC. On its own, CBD has a variety of medicinal and wellness uses. CBD is used to treat seizures, joint pain and inflammation, and as a sleep aid. Because CBD products are not psychoactive and have a significantly lower risk profile they shouldn’t be regulated the same as cannabis products containing THC. Any CBD product with a THC concentration of less than 0.3 per cent (the U.S. legal standard) should be treated as a natural health product. Moving away from the “one size fits all” approach would help make Canada’s legal cannabis market more consumer-friendly in a number of ways.

First, it would exempt CBD products from the heavy-handed marketing, branding and packaging restrictions set out in the Cannabis Act. Regulating cannabis like tobacco rather than alcohol was a huge mistake, given the differences in risks between the two products. But treating CBD products like tobacco is downright silly.

Beyond chipping away at the paternalism built into the Act, exempting CBD would dramatically increase consumer access. The markets for CBD wellness products and beverages, including sports drinks, likely would expand significantly, especially if these products could be sold outside of licensed cannabis retailers, which in many provinces are in short supply. Even in Ontario, which has opened up retail access, some cities — Oakville is one — have maintained their cannabis retail ban. Under a looser regulatory regime, CBD products would be beyond the reach of nanny-state local councilors.

On the industry side, removing CBD products from the Cannabis Act could help reduce the current glut of over one billion grams of cannabis. Freeing the CBD market from the Act would allow producers with too much cannabis on their hands to simply extract the THC and make CBD products.

Reform of the Act should also address the excise tax system for cannabis. Medical cannabis should be exempt, period. We don’t have extra taxes for other medicines. Why this one? Removing the tax may also have the benefit of encouraging medical patients to purchase legal medical cannabis, rather than be pushed into growing their own with a Health Canada permit, an avenue that has regularly been found to be supplying the illicit market.

For recreational users, the $1/gram excise tax should be replaced with a floating percentage. The minimum excise of $1/gram artificially inflates prices, limits the availability of discount brands, and hurts the craft cannabis industry. More competition on price would obviously benefit consumers, but it would also help chip away at black market sales, which are still running at $750 million a year.

Finally, the act should be amended so that the rules for cannabis marketing and promotion are the same as those for alcohol. A legal cannabis brand should be allowed to sponsor events, advertise more broadly, creatively brand its packages, use spokespeople or endorsements, and provide discounts and other inducements for sales — all of which are allowed for alcohol.

To their credit, some provinces have done what they can to make their legal cannabis market more consumer friendly. Ontario, for example, has made significant progress in expanding retail access, and has just committed to permanently legalizing curbside pickup and delivery for cannabis retail stores. These changes at the provincial level are in large part why legal cannabis sales surpassed illegal sales for the first time in the third quarter of 2020.

The provinces seem to be committed to expanding consumer access. With the Cannabis Act now three years old, it’s time for the federal government to step up, too.

Originally published here

Complete PFAS ban not feasible: the EU needs a different approach

Brussels, Belgium – Yesterday, a stakeholder consultation led by the Netherlands, Germany, Denmark, Sweden, and Norway on the use of PFAS (per- and polyfluoroalkyl substances) closed. 

The prospect of an EU PFAS ban is as real as ever, with a number of green groups skewing the discourse towards complete avoidance. In the US, the situation is hardly different, where the PFAS Action Act will soon face a final vote in the Senate.

In response, the Consumer Choice Center’s Maria Chaplia and David Clement published articles in The Parliament Magazine and Real Clear Markets arguing that “while manmade chemicals have their risks, that risk level ultimately depends on each use case and exposure.”

Key points raised in the articles:

“PFAS can be found – but not limited to – in household items and other consumer products, medical equipment, food packaging, and firefighting foam. Their popularity can be explained by their unique qualities, such as chemical resistance and surface tension lowering properties. PFAS’ effectiveness has made them hard and costly to replace”, argue Maria Chaplia and David Clement.

“Some PFAS ban/restrictions might very well be needed and justified but banning an entire category of evolving products won’t serve the consumer. A more appropriate response would be to evaluate these chemicals and substances based on the risk they present and how they are used, rather than lumping them all together and risk enacting bad policy that will have a myriad of consequences”, said Chaplia and Clement

“For example, some of these chemical compounds are vital for contamination-resistant gowns and drapes, implantable medical devices, stent grafts, heart patches, sterile container filters, needle retrieval systems, tracheostomies, catheter guide wire for laparoscopy and inhaler canister coatings. To ban all these chemical compounds, without evaluating the risk associated with each use, puts lifesaving medical technologies in jeopardy and patient safety at risk” 

“Heavyhanded PFAS regulations will also jeopardize the EU smartphone market, used by the vast majority of  Europeans everyday. As cell phones and 5G technology continue to grow and require faster speeds at smaller sizes, these compounds are involved in everything from producing semiconductors to helping cool data centers for cloud computing. Forcibly removing these chemicals from the production process, especially because they present very little risk to humans, will drastically disrupt supply chains and inflate costs that will hurt low-income people the hardest.” argue Chaplia and Clement

John Oliver’s “One Size Fits All” Approach For PFAS Is Misguided

Washington, DC –  British showman and comedian John Oliver, known for his punchy and thorough rants on public policy, has set his sights on a new target: man made chemicals, known as PFAS. In his now viral rant, Oliver explains how PFAS chemicals are problematic for human health and wants all of these chemicals to be declared hazardous by law. This is, in fact, what Congress is attempting to do via the PFAS Action Act, which has passed the House and is waiting for a final vote in the Senate.

David Clement, North American Affairs Manager with the DC based Consumer Choice Center urged caution in regards to regulating these man made chemicals: ” While some bans or restrictions might very well be needed and justified, banning an entire category of evolving products won’t serve the consumer. A more appropriate response would be to evaluate these chemicals and substances based on the risk they present and how they are used, rather than lumping them all together and risk enacting bad policy that will have a myriad of consequences.”

“For example, these chemicals are commonly used to create a long list of medical devices and equipment and done so in a way that presents very little risk to human health. To declare all these chemical compounds hazardous, without evaluating the risk associated with each use, puts lifesaving medical technologies in jeopardy and patient safety at risk,” said Clement

“These chemicals are also used in the production process for smartphones, which 270 million Americans currently use. As cell phones and 5G technology continue to grow and require faster speeds at smaller sizes, these compounds are involved in everything from producing semiconductors to helping cool data centers for cloud computing. Forcibly removing these chemicals from the production process, even when they present very little risk to humans, will drastically disrupt supply chains and inflate costs that will hurt low-income people the hardest,” said Clement.

“Rather than a “one size fits all” approach to PFAS, regulators should keep in mind that risk is established by looking at the hazard a substance presents, and the exposure to that hazard. There is a significant difference between the dumping of these chemicals into water ways, which is atrocious and should never happen, and the necessary use of these chemicals in various production processes, which pose little to no risk to consumer health and safety. Failing to see the difference, and lumping all of these modern chemicals into one regulatory basket, will create a laundry list of negative externalities,” said Clement

Scroll to top
en_USEN